Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma
Ju-Yeon Cho, Moon Seok Choi, Gil Sun Lee, Won Sohn, Jemma Ahn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol. 2016;22(4):477-486.   Published online 2016 Dec 25     DOI: https://doi.org/10.3350/cmh.2016.0048
Citations to this article as recorded by Crossref logo
Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma
Weike Chu, Ping Li, Xue Wu, Peng Zhang, Hui Zhou, Bin Niu
Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Clinical and Molecular Hepatology.2022; 28(2): 207.     CrossRef
Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
Jingjun Huang, Wensou Huang, Yongjian Guo, Mingyue Cai, Jingwen Zhou, Liteng Lin, Kangshun Zhu
Frontiers in Oncology.2021;[Epub]     CrossRef
Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance
Zhimei Huang, Zhixing Guo, Jiayan Ni, Mengxuan Zuo, Tianqi Zhang, Rong Ma, Chao An, Jinhua Huang
International Journal of Hyperthermia.2021; 38(1): 1164.     CrossRef
Radiofrequency ablation with four electrodes as a building block for matrix radiofrequency ablation: Ex vivo liver experiments and finite element method modelling. Influence of electric and activation mode on coagulation size and geometry
Stefaan Mulier, Ricardo Possebon, Yansheng Jiang, Jacques Jamart, Chong Wang, Yi Miao, Tongfu Yu, Kuirong Jiang, Yuanbo Feng, Guy Marchal, Luc Michel, Yicheng Ni
Surgical Oncology.2020; 33: 145.     CrossRef
Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment
Jongduk Kwon, Kwang-Sik Chun, In-Sang Song, Seok-Hwan Kim, Sunjong Han
Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(1): 24.     CrossRef
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clinical and Molecular Hepatology.2020; 26(4): 516.     CrossRef
Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
Hsin-Yeh Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Yi-Hao Yen, Yuan-Hung Kuo, Kwong-Ming Kee, Tatsuo Kanda
PLOS ONE.2020; 15(11): e0242113.     CrossRef
Feasibility, efficacy, and safety of percutaneous MR-guided ablation of small (≤12 mm) hepatic malignancies
Jakob Weiss, Rüdiger Hoffmann, Hansjoerg Rempp, David-Emanuel Keβler, Philippe L. Pereira, Konstantin Nikolaou, Stephan Clasen
Journal of Magnetic Resonance Imaging.2019; 49(2): 374.     CrossRef
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park
The Korean Journal of Internal Medicine.2019; 34(6): 1223.     CrossRef
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients
Adam Doyle, Andre Gorgen, Hala Muaddi, Aloysious D. Aravinthan, Assaf Issachar, Oleg Mironov, Wei Zhang, John Kachura, Robert Beecroft, Sean P. Cleary, Anand Ghanekar, Paul D. Greig, Ian D. McGilvray, Markus Selzner, Mark S. Cattral, David R. Grant, Lesli
Journal of Hepatology.2019; 70(5): 866.     CrossRef
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassine
Critical Reviews in Oncology/Hematology.2018; 129: 44.     CrossRef
A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma
Yao Liu, Le Sun, Fangyuan Gao, Xue Yang, Yuxin Li, Qun Zhang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Ying Feng, Yuyong Jiang, Xianbo Wang
Medicine.2018; 97(49): e13536.     CrossRef
Traitement ablatif pour cancer du rein : modalités d’évaluation pré-, per-, post-intervention et prise en charge adaptée
J. Garnon, T. Tricard, R.L. Cazzato, X. Cathelineau, A. Gangi, H. Lang
Progrès en Urologie.2017; 27(15): 971.     CrossRef
Editorial: rifaximin in cirrhosis-is this what we've been waiting for? Authors’ reply
S. H. Kang, Y. B. Lee, J.-H. Lee
Alimentary Pharmacology & Therapeutics.2017; 46(10): 1017.     CrossRef